Shorts

Mauro Cives, MD, discussed the advantage a T-cell receptor-based approach affords for patients undergoing treatment for pancreatic neuroendocrine tumors, particularly based on an ability to recognize major histocompatibility complex-presenting intracellular peptides.

Uncovering the Unique Advantage of a TCR-Based Approach in Pancreatic NETs

8 months ago

by

Mauro Cives, MD

$In a discussion with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, FASCO, outlined the mechanism of action of gintemetostat (KTX-1001), a novel small molecule inhibitor under evaluation in a phase 1 trial (NCT05651932) among patients with relapsed/refractory multiple myeloma.$

How Does KTX-1001 Target Genetic Abnormalities in Multiple Myeloma?

8 months ago

by

Saad Z. Usmani, MD, MBA, FACP

A Potential Breakthrough in Sarcoma Treatment

A Potential Breakthrough in Sarcoma Treatment

8 months ago

by

Seth M. Pollack, MD

How AI Is Revolutionizing Electronic Health Records

How AI Is Revolutionizing Electronic Health Records

8 months ago

by

Sunil W. Dutta, MD

Meet the team behind the articles, interviews, and shorts posted on CancerNetwork and published in ONCOLOGY.

Meet The CancerNetwork Team

8 months ago

by

Cancer Network Staff

Patrick Borgen, MD, discussed the impact that MRD and ctDNA have played on treatment selection for breast cancer, particularly regarding surgery.

Examining the Impact of ctDNA on Breast Cancer Surgery

8 months ago

by

Patrick I. Borgen, MD

Patient-Centered Care Should Drive Sarcoma Research

Patient-Centered Care Should Drive Sarcoma Research

8 months ago

by

Emily J. Papai, MD

Suzann Duan, PhD, discussed the potential link between immunosenescence and the emergence of immunologically “cold” tumor microenvironments in GEP-NETS.

Is There a Link Between Immunosenescence and “Immune Cold” TMEs in NETs?

8 months ago

by

Suzann Duan, PhD

In a discussion with CancerNetwork®, Ram Prakash Thirugnanasambandam, MBBS, spoke about a manuscript he published in the November/December 2025 issue of the journal ONCOLOGY® focusing on the role that artificial intelligence (AI) can play in palliative care and hematologic malignancies.

Implementing AI as a Supportive Tool in Palliative Oncological Care

8 months ago

by

Ram Prakash Thirugnanasambandam, MBBS

Mauro Cives, MD, discussed a surprising finding in his research, which won an investigator award from the Neuroendocrine Tumor Research Foundation.

Some TILs May Exploit Antitumor Activity in Pancreatic NETs

8 months ago

by

Mauro Cives, MD

$Shambavi Richard, MD, spoke with CancerNetwork® about findings from the phase 1b portion of the DURGA-1 trial (NCT05850234) assessing AZD0120, a novel BCMA/CD19 dual-targeting cellular therapy, among those with relapsed/refractory multiple myeloma.$

AZD0120 Shows “Excellent” Response Rates in R/R Multiple Myeloma

8 months ago

by

Shambavi Richard, MD

Dominique Rash, MD, highlighted what patient factors and characteristics guide how radiation oncologists coordinate utilizing radiation with systemic therapy for patients with inoperable endometrial cancer.

Sequencing Radiation With Systemic Therapy in Inoperable Endometrial Cancer

8 months ago

by

Dominique Rash, MD

Why Survivorship is the Next Phase of Cancer Research

Why Survivorship is the Next Phase of Cancer Research

8 months ago

by

Fumiko Chino, MD

$In a conversation with CancerNetwork® at the 2026 American College of Radiation Oncology (ACRO) Summit, Pranshu Mohindra, MD, discussed the evolution of hypofractionated radiotherapy in the lung cancer field, which may help expedite the treatment process for patients$

How Has Hypofractionation Made Lung Cancer Radiotherapy More Convenient?

8 months ago

by

Pranshu Mohindra, MD

Monzr M. Al Malki, MD, described TRX103, an off-the-shelf allogenic T-cell therapy, contextualized by a presentation he gave at the 2026 Tandem Meetings.

TRX103: The Future of Allogeneic T-Cell Therapy?

8 months ago

by

Monzr Al Malki, MD

When to Use Checkpoint Inhibitors in Sarcoma Therapy

When to Use Checkpoint Inhibitors in Sarcoma Therapy

8 months ago

by

Seth M. Pollack, MD

Vanessa Almendro Navarro, PhD, MBA, encourages her colleagues to envision an ideal state of City of Hope as an organization as opposed to succumbing to the fear of change.

Overcoming Fear to Change in the Commercialization Aspect of Oncology

8 months ago

by

Vanessa Almendro Navarro, PhD, MBA

Irtiza N. Sheikh, DO, touched upon key questions that emerged following the publication of research evaluating liso-cel between patients younger than 50 and those 50 years and older in both the real-world and clinical trial settings.

Highlighting Key Questions in Liso-Cel Treatment Across Lymphoma Settings

8 months ago

by

Irtiza N. Sheikh, DO

Vanessa Almendro Navarro, PhD, MBA, highlighted the importance of collaboration between oncology departments to facilitate drug development for use in oncology care.

Collaboration Across Departments is Key in Oncology Development

8 months ago

by

Vanessa Almendro Navarro, PhD, MBA

Looking back at the long-term effects of the COVID-19 pandemic on oncology care, Daniel C. McFarland, DO, spoke with CancerNetwork® about how this health crisis impacted his interactions with patients from a psycho-oncology perspective.

COVID-19 Was ‘Added Layer of Trauma’ in Psycho-Oncology Care

8 months ago

by

Daniel C. McFarland, DO

Personalizing Diet Based on Patient Risk and Metabolism

Personalizing Diet Based on Patient Risk and Metabolism

8 months ago

by

Ifeoma Dikeocha, PhD

Irtiza N. Sheikh, DO, discussed key efficacy findings from a comparative analysis of liso-cel among patients younger than 50 with large B-cell lymphoma (LBCL) in the real-world and clinical trial settings.

Data Show Similar Liso-Cel Efficacy in Young LBCL Groups Across Settings

8 months ago

by

Irtiza N. Sheikh, DO

The Missing Link in Cancer Research: Diversity

The Missing Link in Cancer Research: Diversity

8 months ago

by

Kathie-Ann Joseph, MD, MPH, FACS

A study published in Lancet Oncology demonstrated that radiation is a feasible method to treat celiac plexus-associated pain in patients with gastrointestinal cancers.

Using Radiation to Treat Celiac Plexus-Associated Pain in GI Cancers

8 months ago

by

Michael Buckstein, MD, PhD

Revolutionizing Breast Cancer: From 7 Weeks to 1 Week of Radiation

Revolutionizing Breast Cancer: From 7 Weeks to 1 Week of Radiation

8 months ago

by

Parul Barry

Beyond Mastectomy: The Power of Oncoplastic Surgery

Beyond Mastectomy: The Power of Oncoplastic Surgery

8 months ago

by

Kathie-Ann Joseph, MD, MPH, FACS

ACRO Day 2 Quick Take With CancerNetwork

ACRO Day 2 Quick Take With CancerNetwork

8 months ago

by

Ariana Pelosci(+1 more)

The Complex Decisions in Treating DCIS Breast Cancer

The Complex Decisions in Treating DCIS Breast Cancer

8 months ago

by

Jean L. Wright, MD, FASTRO

Yun Rose Li, MD, PhD, spoke about the inspiration behind her team’s assessment of cardiovascular risks with hormone therapy for prostate cancer in the phase 2 IMPACT-ADT trial.

STEMI Event Inspires Prostate Cancer Trial Assessing Cardiovascular Risk

8 months ago

by

Yun Rose Li, MD, PhD

As part of a conversation with a CancerNetwork®, Manoj Bhasin, PhD, MS, discussed the next steps for refining the development of next-generation therapies for patients with newly diagnosed multiple myeloma (NDMM) following novel translational findings that he and colleagues published in Nature Cancer.

Translating Cytogenetic Data Into Next-Generation Therapies in NDMM

8 months ago

by

Manoj Bhasin, PhD, MS

Trending on CancerNetwork

Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care

How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy

How to Work With a Patient Who Declines Cancer Treatment

Targeting Cyclin E1, KRAS, and DNA Repair Beyond PARP in Ovarian Cancer

Screening for Depression and Starting Antidepressants in Oncology Care